Ricardo Cruz
Family Medicine · Las Vegas, NVNPI 1104236215
Payments from drug & device makers
Across 105 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$410
- Pfizer$346
- Bayer$259
- Gilead$241
- Novo Nordisk$201
- Corcept Therapeutics$195
- plus $1K from 18 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Food & beverage$2,837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $410 |
| Pfizer | 6 | $346 |
| Bayer | 7 | $259 |
| Gilead | 9 | $241 |
| Novo Nordisk | 10 | $201 |
| Corcept Therapeutics | 8 | $195 |
| Amgen | 10 | $191 |
| Lucid Diagnostics Inc. | 2 | $142 |
| Dexcom, Inc. | 5 | $137 |
| AbbVie | 4 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $92 |
| Ascensia Diabetes Care US Inc. | 1 | $75 |
| Boehringer Ingelheim | 4 | $72 |
| GSK | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Exact Sciences | 3 | $53 |
| Novartis | 2 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| Hologic Sales And Service, LLC | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Boston Scientific | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,837 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 49 | $60,848 |
| OzempicSemaglutide | 44 | $51,217 |
| MounjaroTirzepatide | 29 | $34,982 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,112 |
| FarxigaDapagliflozin Propanediol | 12 | $20,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,865 |
| LinzessLinaclotide | 12 | $8,439 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,989 |
| DilantinPhenytoin Sodium Extended | 12 | $3,709 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,287 |
| Losartan Potassium | 120 | $1,091 |
| Atorvastatin Calcium | 183 | $1,075 |
| Gabapentin | 47 | $725 |
| Metformin Hcl | 92 | $670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $72 | $60,84849 claims |
| Novo NordiskOzempic | $201 | $51,21744 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $410 | $41,15152 claims |
| Lilly USA, LLCMounjaro | $18 | $34,98229 claims |
| GSKTrelegy Ellipta | $66 | $21,11221 claims |
| AbbVieLinzess | $106 | $8,43912 claims |
| PfizerDilantin | $346 | $3,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
- Jerry CadeLas Vegas$381K
- Dana ForteLas Vegas$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.